Sign In
Last checked at 
7 Nov 2016 07:00
EKF Diagnostics Holdings plc
("EKF", the "Company")
Trading update
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that early trading in Q4 of the current financial year has again been materially higher than budget and at a run-rate in excess of already revised market forecasts, upgraded following the trading update provided on 7 October 2016.
The Company now believes that it will achieve revenues of at least £36.5m and adjusted EBITDA for the year ending 31 December 2016 of at least £5.5m, therefore exceeding current market forecasts. The strong performance of the business is due to organic growth.
In addition, the Company announces that cash generation continues to be strong and now expects to be close to breakeven if not cash positive by the year end, and then cash positive in the first quarter, again ahead of the board's previous expectations.
The announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.
EKF Diagnostics Holdings plc | www.ekfdiagnostics.com |
Christopher Mills, Non-Executive Chairman | Tel: 029 2071 0570 |
Julian Baines, CEO | |
Richard Evans, FD & COO | |
Panmure Gordon (UK) Limited (NOMAD & Joint Broker) | Tel: 020 7886 2500 |
Freddy Crossley / Peter Steel (Corporate Finance) | |
N+1 Singer (Joint Broker) | Tel: 020 7496 3000 |
Alex Price / Alex Laughton-Scott | |
Walbrook PR Limited | Tel: 020 7933 8780 or ekf@walbrookpr.com |
Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / 07584 391 303 |
Follow the stocks
